Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144413 | 0.96 | CA1 (0.40) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10144194 | 0.93 | MDM2 (0.39) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10144210 | 0.91 | MDM2 (0.40) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10143385 | 0.90 | MDM2 (0.38) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10144208 | 0.85 | TLR2 (0.40) | TLR2TPSAB1SIRT1SIRT2SIRT5 | |
| SCHEMBL10144432 | 0.84 | CA1 (0.45) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10143509 | 0.84 | CACNA1B (0.39) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10144130 | 0.84 | CA1 (0.39) | TLR2CA1CA2MDM2TLR1 | |
| SCHEMBL10144209 | 0.84 | TLR2 (0.39) | TLR2TPSAB1SIRT1SIRT2SIRT5 | |
| SCHEMBL10144189 | 0.83 | CA1 (0.43) | TLR2CA1CA2MDM2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012009258-A2 | PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS | ROBERTS EDWARD (US) | 2012-01-19 | — | — | WO | disclosed |